520 Results

People

  1. Postow
    Postow
  2. Motzer
    Motzer
  3. Wolchok
    Wolchok
  4. Hellmann
    Hellmann
  5. Shoushtari
    Shoushtari
  6. Voss
    Voss
  7. Callahan
    Callahan
  8. Abou-Alfa
    Abou-Alfa
  9. Jones
    Jones
  10. Rosenberg
    Rosenberg

Groups

  1. Department of Medicine (394)
  2. Solid Tumor Oncology Division (337)
  3. Hematologic Malignancies, Division of (108)
  4. Melanoma and Immunotherapeutics Service (108)
  5. Genitourinary Oncology Service (101)
  6. Melanoma Disease Management Team (96)
  7. GSK Faculty (83)
  8. Surgery (71)
  9. Gastrointestinal Oncology Service (65)
  10. Weinberg Fellows (61)
  1. "nivolumab"
Formats
  1. Journal Article (342)
  2. Review (93)
  3. Editorial (41)
  4. Meeting Abstract (18)
  5. Correspondence (7)
  6. Guidelines (7)
  7. Research Letter (6)
  8. Book Section (4)
  9. Conference Paper (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (394)
  2. Solid Tumor Oncology Division (337)
  3. Hematologic Malignancies, Division of (108)
  4. Melanoma and Immunotherapeutics Service (108)
  5. Genitourinary Oncology Service (101)
  6. Melanoma Disease Management Team (96)

More Groups

People
  1. Michael Postow (55)
  2. Robert Motzer (50)
  3. Jedd Wolchok (41)
  4. Margaret Callahan (28)
  5. Alexander Shoushtari (27)
  6. Matthew Hellmann (26)

More People

Years
  1. 2025 (35)
  2. 2024 (70)
  3. 2023 (75)
  4. 2022 (52)
  5. 2021 (45)
  6. 2020 (64)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (23)
  2. Journal of Clinical Oncology (22)
  3. Journal of Thoracic Oncology (21)
  4. Lancet Oncology (21)
  5. New England Journal of Medicine (19)
  6. Annals of Oncology (17)

More Publications

Publishers
  1. Elsevier Inc. (77)
  2. Elsevier Science, Inc. (50)
  3. Oxford University Press (35)
  4. Wiley Blackwell (32)
  5. Biomed Central Ltd (27)
  6. Nature Publishing Group (27)

More Publishers

Results (520)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Progression-free survival after second line of therapy for metastatic clear cell renal cell carcinoma in patients treated with first-line immunotherapy combinations
    Research Letter

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: A propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
    Journal Article

    Weber, J. S.; Poretta, T.; Stwalley, B. D.; Sakkal, L. A.; Du, E. X.; Wang, T.; Chen, Y.; Wang, Y.; Betts, K. A.; Shoushtari, A. N.
    Cancer Immunology, Immunotherapy (2023)

    Fulltext@MSK | Save
  • Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer
    Review

    Kang, J. J.; Yu, Y.; Chen, L.; Zakeri, K.; Gelblum, D. Y.; McBride, S. M.; Riaz, N.; Tsai, C. J.; Kriplani, A.; Hung, T. K. W.; more...
    CA - A Cancer Journal for Clinicians (2023)

    Fulltext@MSK | Save
  • Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors
    Journal Article

    Zapata, L.; Caravagna, G.; Williams, M. J.; Lakatos, E.; AbdulJabbar, K.; Werner, B.; Chowell, D.; James, C.; Gourmet, L.; Milite, S.; more...
    Nature Genetics (2023)

    Fulltext@MSK | Save
  • Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomised, phase 3 trial
    Journal Article

    Motzer, R. J.; Russo, P.; Grünwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O.; Buti, S.; Barthélémy, P.; Goh, J. C.; Ye, D.; more...
    Lancet (2023)

    Fulltext@MSK | Save
  • Positron emission tomography-computed tomography before autologous stem cell transplant in follicular lymphoma: Coming too late?
    Editorial

    Sarkozy, C.; Salles, G.
    Haematologica (2023)

    Fulltext@MSK | Save
  • Improving systemic therapy for fumarate hydratase–deficient renal cell carcinoma
    Correspondence

    Carlo, M. I.
    European Urology (2023)

    Fulltext@MSK | Save
  • Tumors of the digestive system: Comprehensive review of ancillary testing and biomarkers in the era of precision medicine
    Review

    Molnar, A.; Monroe, H.; Basri Aydin, H.; Arslan, M. E.; Lightle, A.; Lee, H.; El Jabbour, T.
    Current Oncology (2023)

    Fulltext@MSK | Save
  • Phase I study of a multivalent WT1 peptide vaccine (galinpepimut-S) in combination with nivolumab in patients with WT1-expressing ovarian cancer in second or third remission
    Journal Article

    Manning-Geist, B. L.; Gnjatic, S.; Aghajanian, C.; Konner, J.; Kim, S. H.; Sarasohn, D.; Soldan, K.; Tew, W. P.; Sarlis, N. J.; Zamarin, D.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Commentary: Closing the curtain on upfront surgery for esophageal squamous cell carcinoma
    Editorial

    Fairbairn, K.; Molena, D.
    Journal of Thoracic and Cardiovascular Surgery (2023)

    Fulltext@MSK | Save